The Trump administration will require drugmakers to post their list prices in consumer ads under a CMS rule expected Oct. 15, according to Politico.
The move is part of President Donald Trump's blueprint to combat rising drug prices, initially unveiled in May. The agency's proposal has been under review by the White House since August.
"While we cannot comment on pending regulations, the President's 'American Patients First' blueprint to lower prescription drug prices and reduce out-of-pocket costs clearly states that HHS is looking at options to require drug pricing transparency," HHS spokesperson Caitlin Oakley told Politico. "It should not come as a surprise that this would require rulemaking."
Experts caution that the requirement to include list price may be relatively insignificant and may even confuse patients due to the complexity of drug pricing. For example, drugmakers' list prices are mostly used as a starting point for negotiations with pharmacy benefit managers and insurers. Very few patients are asked to pay the full list price.
Drugmakers have strictly opposed the requirement and worked to strip a similar proposal from a funding package last month.
Access the full report here.